Notably, METTL14 has been reported to be required for some cancer development, whereas METTL14 activation shows more tumor‐suppressive activity in a variety of tumors including UCEC (Liu et al, 2018), LIHC (Ma et al, 2017), GBM (Cui et al, 2017), and skin cancer (Yang et al, 2021). The gene discussed is METTL14; the disease is cancer.